Comparative Pharmacology
Head-to-head clinical analysis: NASALCROM versus NEDOCROMIL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NASALCROM versus NEDOCROMIL SODIUM.
NASALCROM vs NEDOCROMIL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cromolyn sodium stabilizes mast cells by inhibiting the release of histamine and other mediators of inflammation from sensitized mast cells. The exact molecular mechanism is not fully understood but may involve inhibition of calcium ion influx into mast cells.
Nedocromil sodium is a mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from mast cells and other inflammatory cells. It also reduces sensory nerve activation and inhibits eosinophil chemotaxis.
One spray (5.2 mg) into each nostril 3-4 times daily (maximum 6 times daily).
2 inhalations (2 mg per inhalation) four times daily via metered-dose inhaler, or 2 inhalations (4 mg per inhalation) twice daily via dry powder inhaler.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours; clinically, due to local mast cell stabilization, systemic levels do not correlate with effect.
Terminal elimination half-life is approximately 2 hours; clinically, this supports twice-daily dosing for sustained effect.
Primarily unchanged drug; renal excretion accounts for ~90% of elimination, with minor biliary/fecal excretion (<5%).
Primarily renal excretion of unchanged drug; approximately 70% excreted in urine and 30% in feces via biliary elimination.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer